

JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 04/15/14

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Acute Coronary Syndrome (2) Stent Thrombosis for Acute Coronary Syndrome (2)	FDA Third Complete Response 2/14 FDA Second Complete Response 2/14 Phase III	
	INVOKANA® (canagliflozin)/VOKANAMET™ (canagliflozin and metformin fixed dose)	Fixed Dose Combination with Metformin (IR) (2)	FDA Complete Response 12/13 - Submitted Response to FDA 2/14 Phase III	Positive CHMP Opinion 2/14
	INVOKANA® (canagliflozin)	Fixed Dose Combination with Metformin (XR) (2) Diabetic nephropathy	Phase III	Phase III
Immunology	STELARA® (ustekinumab) SIMPONI® ARIA™ (golimumab) sirukumab	Crohn's Disease Rheumatoid Arthritis (IV) Rheumatoid Arthritis	Phase III Approved 7/13 Phase III	Phase III File Resubmitted 6/13 Phase III
Infectious Diseases and Vaccines	SIRTURO® (bedaquiline)	Multi-drug resistant tuberculosis (2)	Approved 12/12	Approved 3/14
	PREZISTA® (darunavir) and cobicistat (GS-9350)	Fixed Dose Combination HIV tablet for treatment naïve patients and treatment experienced patients	Filed 3/14	Filed 10/13
	OLYSIO™ (simeprevir)	Chronic hepatitis C virus (HCV) infection for treatment naïve patients (2) Chronic hepatitis C virus (HCV) infection for treatment experienced patients, relapsers, and non-responders (2)	Approved 11/13 Approved 11/13	Positive CHMP Opinion 3/14 Positive CHMP Opinion 3/14
Neuroscience	INVEGA® (paliperidone ER OROS) INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate IM long acting injectable) INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate)	Pediatric indication - adolescent schizophrenia Schizophrenia - 3 month injectable (2) Schizoaffective (2)	Approved 4/11 Phase III Phase III	Filed 3/13 Phase III
Oncology	IMBRUVICA™ (ibrutinib)	Relapsed/refractory patients with Chronic Lymphocytic Leukemia (single agent) (randomized study PCYC-1112) (2)	Filed 4/14	Phase III
		Relapsed/refractory patients with Chronic Lymphocytic Leukemia (single agent) (single arm phase II study PCYC-1102) (2)	Approved 2/14	Filed 10/13
		Relapsed/refractory patients with Chronic Lymphocytic Leukemia (in combination with Bendamustine and Rituximab) (randomized study CLL-3001) (2)	Phase III	Phase III
		Treatment naïve patients with Chronic Lymphocytic Leukemia (single agent) (randomized study PCYC-1115) (2)	Phase III	Phase III
		Relapsed/refractory with Mantle Cell Lymphoma (single agent) (randomized study MCL-3001) (2)	Phase III	Phase III
		Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Mantle Cell Lymphoma (single agent) (single arm phase II study PCYC-1104) (2)	Approved 11/13	Filed 10/13
		Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001)	Phase III	Phase III
	JNJ56021927/ARN-509 siltuximab	Prostate cancer non-metastatic castration-resistant Multicentric Castleman's Disease	Phase III Filed 8/13	Phase III Positive CHMP Opinion 3/14
	VELCADE® (bortezomib) YONDELIS® (trabectedin)	Mantle Cell Lymphoma 1st line (2) Soft Tissue Sarcoma (2) Relapsed Ovarian Cancer	Phase III Phase III	Phase III
ZYTIGA® (abiraterone acetate)	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic		Phase III	

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) Invokana® licensed from Mitsubishi Tanabe Pharma Corporation; Prezista®/cobicistat developed in collaboration with Gilead Sciences; Velcade® developed in collaboration with Millennium; The Takeda Oncology Company; Yondelis® developed in collaboration with PharmaMar S.A.; Xarelto® co-developed with Bayer HealthCare; Invega® Sustenna® developed in collaboration with Alkermes, Inc.; Olysio™ developed in collaboration with Medivir AB; Imbruvica™ developed in collaboration with Pharmacyclics, Inc.; and Sirukumab developed in collaboration with GlaxoSmithKline.



Janssen Pharmaceutical Companies of Johnson & Johnson
Selected Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of April 15, 2014

APPROVED 2013/2014	IN REGISTRATION	PLANNED FILINGS 2014-2017*	
Cardiovascular & Metabolism	Infectious Diseases & Vaccines	Immunology	Infectious Diseases & Vaccines
<p style="text-align: center;">INVOKANA® (canagliflozin) Type 2 diabetes</p>	<p style="text-align: center;">Simeprevir (EU) Chronic Hepatitis C virus</p>	<p style="text-align: center;">Sirukumab Rheumatoid arthritis</p> <p style="text-align: center;">Guselkumab Psoriasis</p>	<p style="text-align: center;">TMC647055/JNJ56914845 (GSK805)/Simeprevir Combination for Chronic Hepatitis C</p>
Infectious Diseases & Vaccines	Oncology	Neuroscience	Oncology
<p style="text-align: center;">OLYSIO™ (US) (simeprevir) Chronic Hepatitis C virus</p> <p style="text-align: center;">SIRTURO® (EU) (bedaquiline) Multi-drug resistant tuberculosis</p>	<p style="text-align: center;">Ibrutinib (EU) Previously treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</p> <p style="text-align: center;">Previously treated Mantle Cell Lymphoma</p> <p style="text-align: center;">Siltuximab Multicentric Castleman's disease</p>	<p style="text-align: center;">Esketamine Treatment resistant depression</p>	<p style="text-align: center;">Daratumumab Refractory multiple myeloma</p> <p style="text-align: center;">YONDELIS® (US) 2nd Line soft tissue sarcoma</p> <p style="text-align: center;">JNJ56021927/ARN-509 pre-metastatic prostate cancer</p>
Oncology			
<p style="text-align: center;">IMBRUVICA™ (US) (ibrutinib) Previously treated Mantle Cell Lymphoma</p> <p style="text-align: center;">Previously treated Chronic Lymphocytic Leukemia</p>			

* Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. INVOKANA® developed in collaboration with Mitsubishi Tanabe Pharma Corporation; OLYSIO™ developed in collaboration with Medivir AB; Sirukumab developed in collaboration with GlaxoSmithKline; IMBRUVICA™ developed in collaboration with Pharmacyclics, Inc.; Daratumumab licensed from Genmab A/S; YONDELIS® developed in collaboration with Pharma Mar S.A.